General Information of This Linker
Linker ID
LIN0HRPQL
Linker Name
Ala-Arg linker
Linker Type
Cathepsin-cleavable linker
Antibody-Linker Relation
Cleavable
Structure
Formula
C11H20BrN5O4
Isosmiles
OC([C@H](CCC/N=C(N)\N)NC([C@H](C)NC(CBr)=O)=O)=O
InChI
InChI=1S/C11H20BrN5O4/c1-6(16-8(18)5-12)9(19)17-7(10(20)21)3-2-4-15-11(13)14/h6-7H,2-5H2,1H3,(H,16,18)(H,17,19)(H,20,21)(H4,13,14,15)/t6-,7-/m0/s1
InChIKey
FUKYPIURTXAEDX-BQBZGAKWSA-N
Pharmaceutical Properties
Molecule Weight
366.216
Polar area
159.9
Complexity
376.842491
xlogp Value
-1.491
Heavy Count
21
Rot Bonds
9
Hbond acc
4
Hbond Donor
5
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
38283215 ADC 2 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.74 ug/mL
High TNF expression (TNF +++)
Method Description
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.

   Click to Show/Hide
In Vitro Model Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia K562 cells (TNF) CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 50 ug/mL Negative TNF expression (TNF-)
Method Description
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.

   Click to Show/Hide
In Vitro Model Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia K562 cells (wt) CVCL_0004
References
Ref 1 Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala-Ala as the optimal dipeptide